González Segundo, López-Soto Alejandro, Suarez-Alvarez Beatriz, López-Vázquez Antonio, López-Larrea Carlos
Department of Functional Biology, University of Oviedo, IUOPA, Oviedo 33006, Spain.
Trends Immunol. 2008 Aug;29(8):397-403. doi: 10.1016/j.it.2008.04.007. Epub 2008 Jul 3.
NKG2D is an activating receptor expressed by NK and T cells. NKG2D ligands show a restricted expression in normal tissues, but they are frequently overexpressed in cancer and infected cells. The binding of NKG2D to its ligands activates NK and T cells and promotes cytotoxic lysis of the cells expressing these molecules. The mechanisms involved in the expression of the ligands of NKG2D play a key role in the recognition of stressed cells by the immune system and represent a promising therapeutic target for improving the immune response against cancer or autoimmune disease. In this review, we analyse the recent advances in understanding the regulation of NKG2D ligand expression and their therapeutic implications.
NKG2D是一种由自然杀伤细胞(NK)和T细胞表达的激活受体。NKG2D配体在正常组织中表达受限,但在癌细胞和受感染细胞中常过度表达。NKG2D与其配体的结合可激活NK细胞和T细胞,并促进表达这些分子的细胞的细胞毒性裂解。NKG2D配体表达所涉及的机制在免疫系统识别应激细胞中起关键作用,并且是改善针对癌症或自身免疫性疾病的免疫反应的一个有前景的治疗靶点。在这篇综述中,我们分析了在理解NKG2D配体表达调控及其治疗意义方面的最新进展。